Dalila Sellami
Novartis
45 Papers
271 Citations
Dalila Sellami is an academic researcher from Novartis. The author has contributed to research in topics: Sonidegib & Medicine. The author has an hindex of 18, co-authored 40 publications.
Chat about Author
Papers
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
Andrew X. Zhu,Masatoshi Kudo,Eric Assenat,Stéphane Cattan,Yoon-Koo Kang,Ho Yeong Lim,Ronnie T.P. Poon,Jean-Frédéric Blanc,Arndt Vogel,Chao-Long Chen,Etienne Dorval,Markus Peck-Radosavljevic,Armando Santoro,Bruno Daniele,Junji Furuse,Annette Jappe,Kevin Perraud,Oezlem Anak,Dalila Sellami,Li-Tzong Chen,Li-Tzong Chen,Li-Tzong Chen +21 more
TL;DR: Everolimus did not improve overall survival in patients with advanced hepatocellular carcinoma whose disease progressed during or after receiving sorafenib or who were intolerant of sorAFenib.
567
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
Michael R. Migden,Alexander Guminski,Ralf Gutzmer,Luc Dirix,Karl D. Lewis,Patrick Combemale,R. Herd,Ragini R. Kudchadkar,Uwe Trefzer,Sven Gogov,Celine Pallaud,Tingting Yi,Manisha Mone,Martin Kaatz,Carmen Loquai,Alexander J. Stratigos,Hans Joachim Schulze,Ruth Plummer,Anne Lynn S. Chang,Frank Cornelis,John T. Lear,Dalila Sellami,Reinhard Dummer +22 more
TL;DR: The benefit-to-risk profile of 200 mg sonidegib might offer a new treatment option for patients with advanced basal cell carcinoma, a population that is difficult to treat.
387
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Angelo Di Leo,Stephen R. D. Johnston,Keun Seok Lee,Eva Ciruelos,Per Eystein Lønning,Wolfgang Janni,Ruth O'Regan,Marie-Ange Mouret-Reynier,Dimitar Kalev,Daniel Egle,Tibor Csőszi,Roberto Bordonaro,Thomas Decker,Vivianne C. G. Tjan-Heijnen,Sibel Blau,Alessio Schirone,Denis Weber,Mona El-Hashimy,Bharani Dharan,Dalila Sellami,Thomas Bachelot +20 more
TL;DR: The safety profile of buparlisib plus fulvestrant does not support its further development in this setting, and the efficacy of buParlisib supports the rationale for the use of the drug in patients with advanced breast cancer.
354
Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study
John T. Lear,Michael R. Migden,Karl D. Lewis,Anne Lynn S. Chang,Alexander Guminski,Ralf Gutzmer,Luc Dirix,Patrick Combemale,Alexandros Stratigos,Ruth Plummer,Henry Castro,Tingting Yi,Manisha Mone,Jocelyn Zhou,Uwe Trefzer,Martin Kaatz,Carmen Loquai,Ragini R. Kudchadkar,Dalila Sellami,Reinhard Dummer +19 more
TL;DR: Patients with locally advanced basal cell carcinoma (laBCC) or metastatic BCC (mBCC), two difficult‐to‐treat populations, have had limited treatment options.
175
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
Reinhard Dummer,Alexander Guminski,Ralf Gutzmer,Luc Dirix,Karl D. Lewis,Patrick Combemale,R. Herd,Martin Kaatz,Carmen Loquai,Alexander J. Stratigos,Hans Joachim Schulze,Ruth Plummer,Sven Gogov,Celine Pallaud,Tingting Yi,Manisha Mone,Anne Lynn S. Chang,Frank Cornelis,Ragini R. Kudchadkar,Uwe Trefzer,John T. Lear,Dalila Sellami,Michael R. Migden +22 more
TL;DR: With longer follow-up, sonidegib demonstrated sustained tumor responses in patients with advanced BCC, and the hedgehog pathway inhibitor vismodegib was not yet approved.
157